New hope for PBC patients: experimental drug K-808 enters Mid-Stage trial
Disease control
Ongoing
This study tests two doses of K-808 (Pemafibrate) in 46 adults with primary biliary cholangitis (PBC) who haven't responded well to standard treatments. The main goal is to see if the drug lowers alkaline phosphatase (ALP) levels, a key marker of liver damage, after 12 weeks. Par…
Phase: PHASE2 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC